Status:

TERMINATED

Evaluation of Continuous Glucose Monitoring in Patients With ACS and Type 2 Diabetes in ICU

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Acute Coronary Syndrome

Type 2 Diabetes

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The investigators hypothesize that the use of a continuous glucose monitoring system (CGMS) can reduce glycemic variability assessed by coefficient of variation (CV) during the acute phase of acute co...

Detailed Description

The aim of this study is to assess the impact of the use of a continuous glucose monitoring system (CGMS) on glycemic variability in diabetic patients admitted in Intensive care unit (ICU) for an acut...

Eligibility Criteria

Inclusion

  • Patient over 18 years old admitted to Cardiac Intensive Care Unit (CICU for acute coronary syndrome (ACS):
  • ACS with STsegment elevation (STEMI), defined by thoracic pain of more than 30 minutes and sus-offset persist of the ST segment at ECG in two contiguous derivations.
  • ACS without ST segment elevation (NSTEMI), defined by a significant elevation of the troponin (\> 99th percentile) with one of the following signs:
  • Symptoms of ischemia
  • Recent modification of the ST or wave segment T to ECG
  • Appearance of a wave q at ECG
  • Loss of segmental viability of myocardial imaging
  • intracoronal thrombus in angiography
  • patient with type 2 diabetes (defined according to the American Diabetes Association (ADA) recommendations) known with:
  • be a hyperglycemia\> 180 mg / dl to admission that requires intravenous insulin therapy
  • Either chronic insulin treatment before admission
  • Patient who has not yet received insulin therapy with intravenous insulin since admission
  • Signed informed consent
  • oral and written comprehension of the French language

Exclusion

  • Patient with hemodynamic instability (shock, catecholamine use, mechanical ventilation, circulatory assistance ...)
  • Patient admitted to the CICU since more than 24 hours
  • Patient requiring Corticotherapy
  • patient with type 1 diabetes (defined according to the ADA recommendations)
  • Needs to perform MRI during CICU stay
  • Pregnancy or breastfeeding
  • patient under legal protection
  • Patient with no social security
  • Patient participating in another interventional research

Key Trial Info

Start Date :

December 7 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 30 2023

Estimated Enrollment :

2 Patients enrolled

Trial Details

Trial ID

NCT04822740

Start Date

December 7 2022

End Date

January 30 2023

Last Update

November 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Lariboisière Hospital

Paris, Île-de-France Region, France, 75475